⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EIKN News
Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
globenewswire.com
EIKN
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
globenewswire.com
EIKN
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
globenewswire.com
EIKN
Eikon Therapeutics to Participate in Investor Conferences in September 2026
globenewswire.com
EIKN
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
globenewswire.com
EIKN
Form 8-K
sec.gov
EIKN
Form 8-K
sec.gov
EIKN
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
globenewswire.com
EIKN
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
globenewswire.com
EIKN
Form 8-K
sec.gov
EIKN